美股周四早盘，基因编辑公司CRISPR Therapeutics（CRSP）下跌1.7%，此前该公司提交文件，计划出售最多6亿美元的普通股，利用其现有的公开市场销售协议。此举旨在加强其财务状况，以推进其研发管线。

海量资讯、精准解读，尽在新浪财经APP

责任编辑：张俊 SF065

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.